PRNewsWire
29 May 2026, 21:31 UTC · 1h ago
Source · https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-receives-two-patent-allowances-spanning-its-actimab-a-and-iomab-act-programs-302786081.html
Read source
Search tags
Story key points
3 claims · impact-rated
The Canadian Intellectual Property Office has issued Notices of Allowance for two patents covering the Actimab-A and Iomab-ACT programs. — Securing intellectual property in a key market reduces competitive risk and increases the long-term valuation of the drug candidates.
+0.30The Actimab-A + CLAG-M combination for AML will have patent protection in Canada running into January 2039. — Extending the exclusivity window for a clinical-stage candidate increases the potential lifetime revenue from the asset.
+0.20The Iomab-ACT conditioning approach for gene-edited cell-based therapies will have patent protection in Canada running into October 2038. — Patent protection for a targeted conditioning agent provides a defensive moat for a high-growth area of cell-based therapy.
+0.20Ticker attribution
Continue reading
6 related stories
Model heads
The company received two patent allowances in Canada, strengthening its intellectual property protection for key radiotherapy programs.
No ticker relationship head found.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
1h ago
